Begin main content

Appropriate Pharmacotherapy for Inflammatory Bowel Disease

Last updated: June 6, 2019
Project Number: HO0003-000 - HE0018-000
Product Line: Technology Review
Result type: Report

In 2018, around 270,000 Canadians were living with inflammatory bowel disease (IBD), which comprises Crohn’s disease and ulcerative colitis. Several drug classes, including corticosteroids, immunomodulators and anti-inflammatory biologics, can induce and maintain remission of IBD. CADTH has undertaken a series of reviews of the clinical and economic evidence surrounding drugs for IBD to clarify their relative place in therapy and inform appropriate reimbursement criteria by public drug plans.